Ann‐Kathrin Eisfeld

This study identifies BRAF mutations in AML, showing poor outcomes and unique co-mutation patterns, suggesting potential targeted therapies.

This study uses single-cell multiomic analysis to reveal genotype-immunophenotype relationships and clonal evolution in NPM1-mutant AML across disease stages.

This study identifies PTPN11 mutations as potential initiating events in AML when paired with NPM1 mutations, revealing their co-driver role and immune diversity in patient samples.

This study identifies circPCMTD1 as a circular RNA that promotes leukemic cell proliferation by enhancing DNA damage response tolerance through a novel peptide product.

This study characterizes myeloid sarcoma through multi-omic profiling, identifies RAS pathway activation as a hallmark, and shows RAS inhibition reduces tumor burden in mouse models.

Pyjacker detects enhancer hijacking in AML, identifying MNX1 activation via 7q deletion as a novel oncogenic mechanism.

The paper develops an ensemble fusion-calling pipeline to improve the detection of clinically relevant gene fusions in pediatric cancer, identifying 67 fusions with a 29.3% diagnostic yield.